News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,734 Results
Type
Article (13948)
Company Profile (304)
Press Release (247482)
Section
Business (79356)
Career Advice (151)
Deals (13190)
Drug Delivery (34)
Drug Development (50331)
Employer Resources (31)
FDA (5682)
Job Trends (5116)
News (144137)
Policy (10018)
Tag
Academia (901)
Alliances (21525)
Alzheimer's disease (758)
Approvals (5665)
Artificial intelligence (68)
Bankruptcy (97)
Best Places to Work (4522)
Biotechnology (249)
Breast cancer (109)
Cancer (890)
Cardiovascular disease (71)
Career advice (132)
CAR-T (73)
Cell therapy (217)
Clinical research (40139)
Collaboration (311)
Compensation (129)
COVID-19 (1006)
C-suite (78)
Cystic fibrosis (67)
Data (984)
Diabetes (87)
Diagnostics (1207)
Drug discovery (57)
Earnings (29005)
Events (47193)
Executive appointments (247)
FDA (6054)
Funding (306)
Gene editing (63)
Gene therapy (163)
GLP-1 (311)
Government (1065)
Healthcare (6543)
Infectious disease (1044)
Inflammatory bowel disease (98)
IPO (7197)
Job creations (859)
Job search strategy (127)
Layoffs (188)
Legal (1375)
Lung cancer (130)
Lymphoma (62)
Manufacturing (87)
Medical device (2559)
Medtech (2560)
Mergers & acquisitions (6128)
Metabolic disorders (260)
Neuroscience (1001)
NextGen Class of 2024 (2004)
Non-profit (847)
Northern California (1092)
Obesity (140)
Opinion (91)
Parkinson's disease (76)
Patents (61)
People (25106)
Phase I (14151)
Phase II (18664)
Phase III (11819)
Pipeline (367)
Postmarket research (851)
Preclinical (5971)
Radiopharmaceuticals (205)
Rare diseases (202)
Real estate (1409)
Regulatory (8289)
Research institute (931)
Southern California (976)
Startups (1964)
United States (8670)
Vaccines (165)
Weight loss (84)
Date
Today (24)
Last 7 days (361)
Last 30 days (1397)
Last 365 days (20551)
2024 (20463)
2023 (22413)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16925)
Australia (2856)
California (2475)
Canada (809)
China (204)
Colorado (91)
Connecticut (104)
Europe (36448)
Florida (272)
Georgia (71)
Illinois (154)
Indiana (61)
Maryland (332)
Massachusetts (1957)
Michigan (56)
Minnesota (101)
New Jersey (631)
New York (684)
North Carolina (419)
Northern California (1092)
Ohio (82)
Pennsylvania (474)
South America (207)
Southern California (976)
Texas (279)
Washington State (248)
261,734 Results for "feldan therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Feldan Therapeutics Announces the treatment of the first patient in the Phase 1/2a clinical trial of its candidate FLD-103, against basal cell carcinoma
October 31, 2024
·
3 min read
Press Releases
FELDAN THERAPEUTICS COMPLETES A US$ 21 MILLION SERIES B FINANCING CO-LED BY GENESYS CAPITAL AND FONDS DE SOLIDARITÉ FTQ
September 4, 2024
·
4 min read
Feldan Therapeutics Secures $16.5m Series B to Bring Lead Asset to Clinical Development
Feldan Therapeutics, a biopharmaceutical company that specializes in the development of treatments based on intracellular delivery of therapeutics, has announced the initial closing of a $16.5 million Series B investment.
June 13, 2023
·
4 min read
Feldan Therapeutics Awarded Funding by Cystic Fibrosis Foundation
Feldan Therapeutics, a biopharmaceutical company that develops therapeutics based on its proprietary intracellular delivery platform, announced it was awarded funding by the Cystic Fibrosis Foundation to pursue the development of the Feldan Shuttle technology as a pulmonary delivery agent for cystic fibrosis.
January 18, 2022
·
1 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Regulatory
FDA Warns Applied Therapeutics of ‘Objectionable Conditions’ in Govorestat Study
The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.
December 4, 2024
·
2 min read
·
Tristan Manalac
Press Releases
NeuroEM Therapeutics(R) Accepted into StartUp Health’s Alzheimer’s Moonshot Community(TM)
September 19, 2024
·
4 min read
Press Releases
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
December 18, 2024
·
16 min read
Feldan Therapeutics Announces Additional Investment in Series A
Feldan Therapeutics (hereafter “Feldan”), a preclinical biotechnology company specialized in the intracellular delivery of therapeutic proteins and peptides, has announced an investment of $1.3 million by Asahi Kasei Corporate Venture Capital (hereafter “AKCVC”).
November 27, 2018
·
2 min read
Complete response letters
Applied Therapeutics Crashes After FDA Rejection of Rare Disease Drug
After extending its review period to evaluate additional submissions, the FDA ultimately denied Applied Therapeutics’ govorestat for galactosemia, citing “deficiencies” with the application. The biotech plans to meet with the regulator to discuss the best way forward for the drug.
December 2, 2024
·
3 min read
·
Tristan Manalac
1 of 26,174
Next
